Merck Targets Sandoz, Intas Over Generic Emend Plans
In two complaints filed May 31 and June 1 in the District of New Jersey, Merck said the abbreviated new drug applications filed by Sandoz and Intas' American unit Accord Healthcare Inc. infringe U.S. Patent Numbers 5,691,336 and 5,716,942, held by Merck.
Merck is asking for an injunction preventing Sandoz and Accord...
Already a subscriber? Click here to login